Post-earnings recap
Reported
Tue, May 3, 2011
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
100%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
This earnings report indicates that Regeneron Pharmaceuticals faced challenges this quarter, particularly reflected in the negative EPS. The stock dropped 4.84% in reaction to the disappointing earnings, signaling investor concern. Without guidance, uncertainty remains about the company's near-term performance and strategy.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.49 | N/A | -27.94% |
| Revenue | N/A | N/A | N/A |
Management expressed concerns about recent performance but remains committed to future strategies. They did not provide specific guidance for upcoming quarters.
Management acknowledged the challenges faced this quarter.
They emphasized a focus on long-term growth despite current setbacks.